A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Clinical trial NCT01232712 · COMPLETED
Trial details
- NCT number
- NCT01232712
- Sponsor
- Vaxil Therapeutics Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-01
- Primary completion
- 2013-05-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.